This section gives some more detailed guidance around the issues to consider in the early stage of a company’s operations.
GNES8: The Importance of Learning Agility
GNES 7: The Good And Bad of Video Interviewing
GNES 5: Creating a company culture that attracts and retains talent during and post-global pandemic
GNES 4: Attracting the right talent in the times of coronavirus – Job Description as a Talent Magnet
GNES 2: Recruit for future-proof profiles
GNES 1: Differences in recruiting for a big pharma and a small biotech
GNL 21: Licensing manufacturers, wholesale dealers and brokers
GNL 19: Pre-clinical, clinical and post-market surveillance
GNL 15: Keeping Your Confidential Information and Staff Safe From Competition
GNL 14: Medical Devices Regulation – The New Rules
GNL 13: Medical Devices Regulation – The Current Rules
GNL 9: Licensing Patents – Royalties, Warranties & Indemnities and Termination
GNL 8: Licensing Patents – Exclusivity, Territory, Duration and Improvements
GNL 5: Drafting Commercial Agreements – Endeavours and Entire Agreement Clauses, and Contractual Time Bars
GNL 4: Research, Development and Collaboration Agreements
GNP 9: Procedural Overview of Seeking Patent Protection Abroad
GNP 8: Trade Mark Usage
GNP 6: IP Strategy Essentials
GNP 4: The Pros and Cons of Filing a Patent
GNP 3: Why Should Small Life Science Companies Care About Patents?
GNP 2: Patent Fundamentals
GNP 1: Intellectual Property Basics
GNT69: Making Tax Digital for Corporation Tax
GNT68: Making Tax Digital for VAT
GNT 67: Non-resident directors
GNT 65: A tax overview of share schemes and other equity incentives
GNT 64: Off payroll workers : IR35 for the private sector from April 2021
GNT 57: Trading Company Status
GNT 58: Corporate Criminal Offence – As Applied to Life Sciences
GNT 54: PAYE Settlement Agreements (PSAs)
GNT 10: EMI Share Options
GNT 31: SME R&D Tax Credit and RDEC Comparison
GNT 27: SME R&D Regime Essentials
GNT 9: Compliance Best Practice for Development Companies